Guillermo Garcia‐Manero

Research interests

Publications

• Genomic profiling for clinical decision making in myeloid neoplasms and acute leukemia

  Blood · 2022 · https://doi.org/10.1182/blood.2022015853

• Acute myeloid leukemia: current progress and future directions

  Blood Cancer Journal · 2021 · https://doi.org/10.1038/s41408-021-00425-3

• Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia

  Journal of Clinical Oncology · 2021 · https://doi.org/10.1200/jco.20.03736

• Phase I First-in-Human Dose Escalation Study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms

  Leukemia · 2021 · https://doi.org/10.1038/s41375-021-01328-9

• SF3B1-mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDS

  Blood · 2020 · https://doi.org/10.1182/blood.2020004850

• 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial

  The Lancet Haematology · 2020 · https://doi.org/10.1016/s2352-3026(20)30210-6

• Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes

  New England Journal of Medicine · 2020 · https://doi.org/10.1056/nejmoa1908892

• TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups

  Leukemia · 2019 · https://doi.org/10.1038/s41375-018-0351-2

• PPM1D Mutations Drive Clonal Hematopoiesis in Response to Cytotoxic Chemotherapy

  Cell stem cell · 2018 · https://doi.org/10.1016/j.stem.2018.10.004

• Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II Study

  Cancer Discovery · 2018 · https://doi.org/10.1158/2159-8290.cd-18-0774

• Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: long-term follow-up of a single-centre, phase 2 study

  The Lancet Haematology · 2018 · https://doi.org/10.1016/s2352-3026(18)30176-5

• Clinical experience with the BCL 2‐inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies

  American Journal of Hematology · 2017 · https://doi.org/10.1002/ajh.25000

• Ph-like acute lymphoblastic leukemia: a high-risk subtype in adults

  Blood · 2016 · https://doi.org/10.1182/blood-2016-07-726588

• Time-dependent changes in mortality and transformation risk in MDS

  Blood · 2016 · https://doi.org/10.1182/blood-2016-02-700054

• Myelodysplastic Syndromes, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology

  Journal of the National Comprehensive Cancer Network · 2016 · https://doi.org/10.6004/jnccn.2017.0007

• Impact of complete molecular response on survival in patients with Philadelphia chromosome–positive acute lymphoblastic leukemia

  Blood · 2016 · https://doi.org/10.1182/blood-2016-03-707562

• Validation of WHO classification-based Prognostic Scoring System (WPSS) for myelodysplastic syndromes and comparison with the revised International Prognostic Scoring System (IPSS-R). A study of the International Working Group for Prognosis in Myelodysplasia (IWG-PM)

  Leukemia · 2015 · https://doi.org/10.1038/leu.2015.55

• Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study

  The Lancet Oncology · 2015 · https://doi.org/10.1016/s1470-2045(15)00207-7

• Deregulation of innate immune and inflammatory signaling in myelodysplastic syndromes

  Leukemia · 2015 · https://doi.org/10.1038/leu.2015.69

• An international consortium proposal of uniform response criteria for myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in adults

  Blood · 2015 · https://doi.org/10.1182/blood-2014-10-607341

• TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients

  Blood · 2014 · https://doi.org/10.1182/blood-2014-06-582809

• CCAT2 , a novel noncoding RNA mapping to 8q24, underlies metastatic progression and chromosomal instability in colon cancer

  Genome Research · 2013 · https://doi.org/10.1101/gr.152942.112

• New Comprehensive Cytogenetic Scoring System for Primary Myelodysplastic Syndromes (MDS) and Oligoblastic Acute Myeloid Leukemia After MDS Derived From an International Database Merge

  Journal of Clinical Oncology · 2012 · https://doi.org/10.1200/jco.2011.35.6394

• Revised International Prognostic Scoring System for Myelodysplastic Syndromes

  Blood · 2012 · https://doi.org/10.1182/blood-2012-03-420489

• Genetic Alterations Activating Kinase and Cytokine Receptor Signaling in High-Risk Acute Lymphoblastic Leukemia

  Cancer Cell · 2012 · https://doi.org/10.1016/j.ccr.2012.06.005

• K-rasG12V transformation leads to mitochondrial dysfunction and a metabolic switch from oxidative phosphorylation to glycolysis

  Cell Research · 2011 · https://doi.org/10.1038/cr.2011.145

• Clinical Effect of Point Mutations in Myelodysplastic Syndromes

  New England Journal of Medicine · 2011 · https://doi.org/10.1056/nejmoa1013343

• Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia

  Blood · 2010 · https://doi.org/10.1182/blood-2010-03-276485

• Chemoimmunotherapy With a Modified Hyper-CVAD and Rituximab Regimen Improves Outcome in De Novo Philadelphia Chromosome–Negative Precursor B-Lineage Acute Lymphoblastic Leukemia

  Journal of Clinical Oncology · 2010 · https://doi.org/10.1200/jco.2009.26.9456

• Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies

  Blood · 2009 · 10.1182/blood-2009-03-210039

• A germline JAK2 SNP is associated with predisposition to the development of JAK2V617F-positive myeloproliferative neoplasms

  Nature Genetics · 2009 · https://doi.org/10.1038/ng.342

• Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia

  Blood · 2006 · https://doi.org/10.1182/blood-2006-05-021162

• Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high‐risk myelodysplastic syndrome:

  Cancer · 2006 · https://doi.org/10.1002/cncr.21723

• Phase 1/2 study of the combination of 5-aza-2′-deoxycytidine with valproic acid in patients with leukemia

  Blood · 2006 · https://doi.org/10.1182/blood-2006-03-009142

• Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2′-deoxycytidine (decitabine) in hematopoietic malignancies

  Blood · 2003 · https://doi.org/10.1182/blood-2003-03-0687

Current projects

No projects listed.